FC
CRSP icon

FORA Capital’s CRISPR Therapeutics CRSP Stock Holding History

FORA Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Buy
+5,668
New +$299K 0.02% 306
2021
Q2 		– Sell
-1,986
Closed -$242K – 920
2021
Q1 		$242K Sell
1,986
-13,560
-87% -$2.05M 0.08% 259
2020
Q4 		$2.38M Buy
15,546
+15,029
+2,907% +$1.78M 0.36% 56
2020
Q3 		$43K Sell
517
-10,198
-95% -$905K 0.03% 460
2020
Q2 		$787K Buy
+10,715
New +$627K 0.27% 92
2020
Q1 		– Sell
-2,598
Closed -$158K – 1080
2019
Q4 		$158K Buy
+2,598
New +$142K 0.02% 669

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

FORA Capital's CRSP Position: Q2 2026 in Review

FORA Capital opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 5,668 shares worth $309K. The stake represents 0.02% of the portfolio and ranks #306 among its holdings. This is a return to the name: FORA Capital previously reported a position in CRSP as recently as Q1 2021.

FORA Capital first reported a position in CRSP in Q4 2019 and has held it in 6 quarters since. The position peaked at $2.38M in Q4 2020. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • FORA Capital held 5,668 shares of CRISPR Therapeutics worth $309K as of Q2 2026.
  • CRISPR Therapeutics was a new FORA Capital position in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of FORA Capital's portfolio in Q2 2026, its #306 holding.
  • FORA Capital first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 6 quarters since.
  • FORA Capital's CRISPR Therapeutics position peaked at $2.38M in Q4 2020.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.